Treatment Information

Back

Colon Cancer treatment details. Chemotherapy.

Monash University, Melbourne, Australia.

Survival: monthsCountry:Australia
Toxiciy Grade:5City/State/Province:Melbourne
Treatments:ChemotherapyHospital:Monash University
Drugs:Journal:Link
Date:Jan 2011

Description:

Patients:
This study involved patients with metastatic colorectal cancer who had received prior chemotherapy. Patients were divided into two separate treatment groups. Group A consisted of 35 patients with a median age of 64 years and 21 were male. Group B had 41 patients with a median age of 63 years and 24 were male.

Treatment:
Group A was treated with the chemotherapy agent irinotecan. Group B was treated with irinotecan that was formulated with the drug carrier hyaluronan, called HA-irinotecan.

Toxicities:
In group A, there were 3 treatment-related deaths reported due to neutropenic sepsis (infection), respiratory failure, and an unknown cause. Grade 3 diarrhea, nausea, and vomiting were also reported.

The maximum toxicity grade in group B was grade 4, including mucosal inflammation, neutropenia, and leucopenia. Grade 3 diarrhea, nausea, and vomiting were also reported.

Results:
The reported median overall survival was 8.0 months for group A and 10.1 months for group B.

Support:
This study was supported by Alchemia Oncology, the makers of HA-irinotecan.

Correspondence: Dr. Tracy Brown; email: [email protected]



Back